Pioneering the chemistry of early detection.
DatChem is addressing unmet patient needs through analysis of patient data on a cloud-based platform, leading to earlier interventions and better patient outcomes.
A clinical breakthrough, two decades in the making.
Scientific and clinical research into MRS technology has been performed by the founders of DatChem over more than two decades.
They created DatChem Data Intelligence (DDI) for data acquisition and analysis, enabling DatChem to measure, non-invasively, the level of specific disease biomarkers. In doing so, DatChem has made a clinical breakthrough in the application of Magnetic Resonance Spectroscopy (MRS).
We believe this technology will change the way doctors and other health practitioners identify, diagnose and treat disease.
Advanced procedures, no new hardware.
DatChem extends what an MRI can do, turning a routine scan into a non-invasive read of tissue chemistry, interpreted in the cloud.
Magnetic Resonance Spectroscopy
A clinical breakthrough in the application of MRS, reading the chemistry of tissue from a standard scan, with no contrast and no biopsy.
DatChem Data Intelligence
Our proprietary DDI engine acquires and analyses spectral data, measuring the level of specific disease biomarkers against exclusive databases.
Cloud-based platform
A scalable, secure cloud application interprets each study in minutes, with data sovereignty respected on a regional basis.
Proof, in the clinic and the lab.
DatChem has a clear path to FDA approval, with three clinical sites operating across Australia, Europe and the United States.
- Longitudinal breast study completed (2012–2024), 32 of 33 cancers correctly predicted.
- PTSD & blast-overpressure trial completed, funded by the USA CTTSO.
- SaaS platform built and operating in the cloud.
- Three clinical sites live across Australia, Europe and the US.
- Regulatory approval: a clear path to FDA, with TGA & EMA to follow.
- Siemens Healthineers: a relationship since 1999, formalised by a 2026 LOI.
- ADHD clinical trial: beginning in Australia, with intent to progress globally.
- Commercialisation across selected global markets.
Built to medical-device standard.
A commercial quality management system governs the structure, procedures and resources behind DatChem, covering every step from the moment data leaves the scanner to the report posted back to the PACS, for compliance with FDA, EMA and TGA requirements.
Quality management systems
Medical devices, quality management systems, requirements for regulatory purposes.
Risk management
Medical devices, the application of risk management to medical devices.
Software life cycle
Medical device software, software life-cycle processes, governing data from scanner to report.
Siemens Healthineers is assisting with this process, alongside any further ISO standards applicable to our software device.
Current clinical & research collaborators
A robust portfolio across the US, EU & Australia.
Nine granted patents and twelve pending applications spanning breast-cancer detection, PTSD, pain, ADHD and the underlying spectroscopy architecture, backed by an international patent strategy.
Board of Directors.
Carolyn Mountford
Peter Malycha
David Purdue
Tim McLennan
James Malycha
Sarah Mountford-Bunn
Andrew Mountford-Bunn
The DatChem Team.
Clinicians, scientists, engineers and advocates building the future of early detection.
Gorane Santamaria
John Irvine
Laura Mariano
David Crompton
Rosanna Tremewan
Jason Beard
Julia Watson
Laurie Kear
Dr. Budi Jap
Lisa Rich
Darren Lukas
Natali Naude
Tyrone Humphries
Graham Galloway
Neha Chaudhary
Wendy Dean
Better care through DatChem.
For clinical, commercial, partnership or investment enquiries, our team would be glad to hear from you.